Finerenone Shows Cardiovascular and Kidney Benefits Across CKM Stages in Type 2 Diabetes and CKD
Episode Summary
Finerenone reduced cardiovascular and kidney events across CKM stages in adults with diabetes and CKD, supporting broader risk assessment alongside individualized treatment and monitoring.